- Home
- GRNT vs ACHV Comparison
GRNT vs ACHV Comparison
Compare GRNT & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRNT | ACHV |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 667.4M | 726.5M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GRNT | ACHV |
|---|---|---|
| Price | $5.90 | $6.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $8.20 | ★ $14.15 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 7.45% | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $450,306,000.00 | N/A |
| Revenue This Year | $40.45 | N/A |
| Revenue Next Year | $4.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.49 | N/A |
| 52 Week Low | $4.18 | $2.62 |
| 52 Week High | $6.15 | $8.64 |
Technical Indicators
Market Signals| Indicator | GRNT | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 77.56 | 37.54 |
| Support Level | $4.76 | $6.22 |
| Resistance Level | $6.12 | $6.64 |
| Average True Range (ATR) | 0.21 | 0.35 |
| MACD | 0.12 | -0.05 |
| Stochastic Oscillator | 95.76 | 25.40 |
Price Performance
Historical ComparisonAbout GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.